Do you want to read an article? Please log in or register.
Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of Pseudomonas aeruginosa
Bronchi
RECOMMENDED
Related content
COPD
Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study
Respiration.
Rodrigo-Troyano A, Melo V, Marcos PJ, Laserna E, Peiro M, Suarez-Cuartin G, Perea L, Feliu A, Plaza V, Faverio P, Restrepo MI, Anzueto A, Sibila O
doi: 10.1159/000490190.
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
RECOMMENDED
Pulmonary FibrosisBronchi
Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Kwok WC, Ho JCM, Tam TCC, Ip MSM, Lam DCL
doi: 10.1186/s12931-021-01729-5
RECOMMENDED
Further Publications
Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Choate R, Aksamit TR, Mannino D, Addrizzo-Harris D, Barker A, Basavaraj A, Daley CL, Daniels MLA, Eden E, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, McShane PJ, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL, Stone G
doi: 10.1016/j.rmed.2020.106285
RECOMMENDED
Bronchi
Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis
Respir Med.
Alcaraz-Serrano V, Fernández-Barat L, Scioscia G, Llorens-Llacuna J, Gimeno-Santos E, Herrero-Cortina B, Vàzquez N, Puig de la Bellacasa J, Gabarrús A, Amaro-Rodriguez R, Menéndez R, Torres A
doi: 10.1016/j.rmed.
RECOMMENDED
Bronchi
Antimicrobial peptides, disease severity and exacerbations in bronchiectasis
Thorax.
Sibila O, Perea L, Cantó E, Shoemark A, Cassidy D, Smith AH, Suarez-Cuartin G, Rodrigo-Troyano A, Keir HR, Oriano M, Ong S, Vidal S, Blasi F, Aliberti S, Chalmers JD
doi: 10.1136/thoraxjnl-2018-212895.
RECOMMENDED
Pulmonary Fibrosis
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Am J Respir Crit Care Med.
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, Graff GR, Kerby GS, Orenstein D, Buckingham R, Ramsey BW; OPTIMIZE Study Group
doi: 10.1164/rccm.
RECOMMENDED
Bronchi
Validation of the Bronchiectasis Impact Measure (BIM) - a novel patient reported outcome measure
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Crichton ML, Dudgeon EK, Shoemark A, Chalmers JD
doi: 10.1183/13993003.03156-2020
RECOMMENDED
Bronchi
Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial
Lancet.
Goyal V, Grimwood K, Byrnes CA, Morris PS, Masters IB, Ware RS, McCallum GB, Binks MJ, Marchant JM, van Asperen P, O'Grady KF, Champion A, Buntain HM, Petsky H, Torzillo PJ, Chang AB
doi: 10.1016/S0140-6736